Rule 3.8A

Appendix 3E

Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

e of entity		ABN/ARSN			
Sigma Pharmaceuticals Limited		15 088 417 403			
(the entity) give ASX the following	information.				
ormation about buy-back					
Type of buy-back	On-market buy-back				
Date Appendix 3C was given to ASX	13 September 2012 (Associated Appendix 3D dated 18 November 2015)				
Total of all shares/units bought back, or in relation to which acceptances have been received, before, and on, previous day					
	Before previous day	Previous day			
Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been received	112,335,506	164,599			
_	фоо осо эээ	1			
Total consideration paid or payable for the shares/units	\$82,068,323	\$192,120			
	(the entity) give ASX the following ormation about buy-back Type of buy-back Date Appendix 3C was given to ASX cal of all shares/units bought been received, before, and Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been received	(the entity) give ASX the following information. Ormation about buy-back Type of buy-back Date Appendix 3C was given to ASX Date Appendix 3C was given to ASX Type of all shares/units bought back, or in relation to the been received, before, and on, previous day Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which			

Before previous day	Previous day
---------------------	--------------

5 If buy-back is an on-market buyback

Highest pi \$1.1750	rice paid:		Highest price paid: \$1.1800	
Lowest \$0.5600	price	paid:	Lowest price paid: \$1.1400	
V OIGGG			Highest price allowed under rule 7.33: \$1.1858	

How many shares/units may still be bought back?

6 If the company/trust has disclosed an intention to buy back a maximum number of shares/units – the remaining number of shares/units to be bought back

6,130,247			

Compliance statement

- 1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

or, for trusts only:

- 1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here:

Date: 5 July 2016

(Director/Company secretary)

Print name: Sam Lawson